Suppr超能文献

伪装的血红蛋白变体。

Hemoglobin variant in disguise.

机构信息

DynaLIFE Medical Labs, Edmonton, AB, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Newborn Screening Laboratory, Alberta Precision Laboratories, University of Alberta Hospital, Edmonton, AB, Canada; Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.

出版信息

Clin Biochem. 2023 Aug;118:110589. doi: 10.1016/j.clinbiochem.2023.110589. Epub 2023 May 24.

Abstract

BACKGROUND

Hemoglobinopathies include thalassemia syndromes, where production of one or more globin subunits of hemoglobin (Hb) is reduced, and structural Hb variants. Over 1000 disorders of Hb synthesis and/or structure have been identified and characterized, with phenotypes ranging from having severe clinical manifestations to clinically silent. Various analytical methods are used to phenotypically detect Hb variants. However, molecular genetic analysis is a more definitive method for Hb variant identification.

CASE REPORT

Here, we report a case of a 23-month-old male with results from capillary electrophoresis, gel electrophoresis (acid and alkaline), and high-performance liquid chromatography most consistent with HbS trait. Specifically, capillary electrophoresis showed slightly elevated HbF and HbA2, HbA of 39.4% and HbS of 48.5%. The HbS percentage was consistently higher than expected (typically 30-40%) for HbS trait with no concurrent thalassemic indices. The patient has not experienced any clinical complications due to the hemoglobinopathy and he is thriving.

CONCLUSION

Molecular genetic analysis revealed the presence of compound heterozygosity for HbS and Hb Olupona. Hb Olupona is an extremely rare beta-chain variant that appears as HbA on all three common methods used for phenotypic Hb analysis. When the fractional concentration of Hb variants is unusual, more definitive methods should be used, such as mass spectrometry or molecular genetic testing. In this case, incorrectly reporting this result as HbS trait is unlikely to have a significant clinical impact, as current evidence suggests Hb Olupona is not a clinically significant variant.

摘要

背景

血红蛋白病包括地中海贫血综合征,其中血红蛋白(Hb)的一个或多个球蛋白亚基的产生减少,以及结构 Hb 变体。已经鉴定和表征了超过 1000 种 Hb 合成和/或结构的疾病,表型范围从具有严重临床表现到临床无症状。各种分析方法用于表型检测 Hb 变体。然而,分子遗传学分析是 Hb 变体识别的更确定方法。

案例报告

在这里,我们报告了一例 23 个月大的男性病例,毛细管电泳、凝胶电泳(酸和碱性)和高效液相色谱的结果最符合 HbS 特征。具体来说,毛细管电泳显示 HbF 和 HbA2 略有升高,HbA 为 39.4%,HbS 为 48.5%。HbS 的百分比始终高于 HbS 特征的预期(通常为 30-40%),没有同时出现地中海贫血指数。该患者由于血红蛋白病没有经历任何临床并发症,并且生长良好。

结论

分子遗传学分析显示存在 HbS 和 Hb Olupona 的复合杂合性。Hb Olupona 是一种极其罕见的β链变体,在用于表型 Hb 分析的所有三种常见方法上均表现为 HbA。当 Hb 变体的分数浓度异常时,应使用更确定的方法,例如质谱或分子遗传学检测。在这种情况下,错误地将此结果报告为 HbS 特征不太可能产生重大临床影响,因为目前的证据表明 Hb Olupona 不是一种具有临床意义的变体。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验